Getting the Motor Running
More Hands on Molecular Deck Key to Heart Failure Treatment
By Anette Breindl
Cytokinetics Inc's lead compound, omecamtiv mecarbil, is in Phase II trials for the treatment of heart failure. In the March 18, 2011, issue of Science, researchers from Cytokinetics and colleagues at several academic institutions published details of how the drug works. Those insights may yield new treatments for heart failure as well as other diseases where muscle contraction is an issue, such as asthma.